FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Carlos Arteaga

Research Profile

Disorders

Breast Neoplasms

Chemicals & Drugs

Living Beings

Physiology

Anatomy

Phenomena

Phosphorylation

Co-author Network

Publications

TOP 3
Neil E Bhola; Rebecca S Cook; Teresa C Dugger; María Gabriela Kuba; Violeta Sánchez; Melinda Sanders; Jamie Stanford; Justin M Balko; Carlos L Arteaga
TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer.
Takafumi Sangai; Emily Tarco; Yun Wu; Todd W Miller; Gordon B Mills; Argun Akcakanat; Carlos L Arteaga; Huiqin Chen; Kim-Anh Do; Ana Maria Gonzalez-Angulo; Funda Meric-Bernstam
Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.
Justin M Balko; Levi A Garraway; Maria G Kuba; Ingrid A Mayer; Ingrid M Meszoely; Todd W Miller; Melinda E Sanders; Nikhil Wagle; Carlos L Arteaga
Discordant cellular response to presurgical letrozole in bilateral synchronous ER+ breast cancers with a KRAS mutation or FGFR1 gene amplification.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Carlos Arteaga (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Neil E Bhola; Rebecca S Cook; Teresa C Dugger; María Gabriela Kuba; Violeta Sánchez; Melinda Sanders; Jamie Stanford; Justin M Balko; Carlos L Arteaga
TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer.
The Journal of clinical investigation 2013;123(3):1348-58.
2012: Takafumi Sangai; Emily Tarco; Yun Wu; Todd W Miller; Gordon B Mills; Argun Akcakanat; Carlos L Arteaga; Huiqin Chen; Kim-Anh Do; Ana Maria Gonzalez-Angulo; Funda Meric-Bernstam
Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(20):5816-28.
2012: Justin M Balko; Levi A Garraway; Maria G Kuba; Ingrid A Mayer; Ingrid M Meszoely; Todd W Miller; Melinda E Sanders; Nikhil Wagle; Carlos L Arteaga
Discordant cellular response to presurgical letrozole in bilateral synchronous ER+ breast cancers with a KRAS mutation or FGFR1 gene amplification.
Molecular cancer therapeutics 2012;11(10):2301-5.
2012: Justin M Balko; Neil E Bhola; Rebecca S Cook; Mitch Dowsett; Henry L Gómez; Ana M González-Angulo; Nara M Granja-Ingram; María G Kuba; Ingrid M Meszoely; Todd W Miller; Gordon B Mills; Joseph A Pinto; Janine Salter; Melinda E Sanders; J Joshua Smith; Katherine Stemke-Hale; David B Vaught; Carlos L Arteaga
Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance.
Nature medicine 2012;18(7):1052-9.
2012: Alexa B Turke; Youngchul Song; Carlos L Arteaga; John M Asara; Rebecca Cook; Carlotta Costa; Jeffrey A Engelman
MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors.
Cancer research 2012;72(13):3228-37.
2012: Justin M Balko; Carlos L Arteaga
Molecular signatures of lung cancer: defining new diagnostic and therapeutic paradigms.
Molecular diagnosis & therapy 2012;16(1):1-6.
2011: Joan T Garrett; Anindita Chakrabarty; Carlos L Arteaga
Will PI3K pathway inhibitors be effective as single agents in patients with cancer?
Oncotarget 2011;2(12):1314-21.
2011: Emily M Fox; Ana María González-Angulo; Maria G Kuba; Shuying Liu; H Charles Manning; Todd W Miller; Gordon B Mills; Violeta Sánchez; Yu Shyr; R Adam Smith; Fei Ye; Justin M Balko; Elizabeth Buck; Carlos L Arteaga
A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer.
Cancer research 2011;71(21):6773-84.
2011: B N Rexer; C Rinehart; N de Matos Granja-Ingram; J C Chang; B Dave; A M González-Angulo; A-J L Ham; S Hill; D C Liebler; G B Mills; Carlos L Arteaga
Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition.
Oncogene 2011;30(40):4163-74.
2011: Xuemei Yang; Carlos L Arteaga; Lewis C Cantley; Jeffrey A Engelman; Pasi A Janne; Todd W Miller; Jie Qi; Brent N Rexer; Youngchul Song; Alexa B Turke; John M Asara
Using tandem mass spectrometry in targeted mode to identify activators of class IA PI3K in cancer.
Cancer research 2011;71(18):5965-75.
2011: Todd W Miller; William R Miller; Gordon B Mills; Yu Shyr; R Adam Smith; Helen Anderson; Justin M Balko; Siprachanh Chanthaphaychith; Mitch Dowsett; Anita K Dunbier; Emily M Fox; Zara Ghazoui; Ana M González-Angulo; Catherine Higham; Aixiang Jiang; Maria G Kuba; Sauveur-Michel Maira; H Charles Manning; Carlos L Arteaga
ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer.
Cancer discovery 2011;1(4):338-51.
2011: Stefan Glück; Carlos L Arteaga; C Kent Osborne
Optimizing chemotherapy-free survival for the ER/HER2-positive metastatic breast cancer patient.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(17):5559-61.
2011: Amy Chow; Carlos L Arteaga; Shizhen Emily Wang
When tumor suppressor TGFβ meets the HER2 (ERBB2) oncogene.
Journal of mammary gland biology and neoplasia 2011;16(2):81-8.
2011: Joan T Garrett; Carlos L Arteaga
Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications.
Cancer biology & therapy 2011;11(9):793-800.
2011: Justin M Balko; Carlos L Arteaga
Dead-box or black-box: is DDX1 a potential biomarker in breast cancer?
Breast cancer research and treatment 2011;127(1):65-7.
2011: Todd W Miller; Justin M Balko; Zara Ghazoui; Anita K Dunbier; Helen Anderson; Mitch Dowsett; Ana M González-Angulo; Gordon B Mills; William R Miller; Huiyun Wu; Yu Shyr; Carlos L Arteaga
A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(7):2024-34.
2011: Joan T Garrett; María Graciela Olivares; Cammie Rinehart; Nara D Granja-Ingram; Violeta Sánchez; Anindita Chakrabarty; Bhuvanesh Dave; Rebecca S Cook; William Pao; Eliot McKinely; H C Manning; Jenny Chang; Carlos L Arteaga
Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase.
Proceedings of the National Academy of Sciences of the United States of America 2011;108(12):5021-6.
2011: Ritwik Ghosh; Archana Narasanna; Shizhen Emily Wang; Shuying Liu; Anindita Chakrabarty; Justin M Balko; Ana María González-Angulo; Gordon B Mills; Elicia Penuel; John Winslow; Jeff Sperinde; Rajiv Dua; Sailaja Pidaparthi; Ali Mukherjee; Kim Leitzel; Wolfgang J Kostler; Allan Lipton; Michael Bates; Carlos L Arteaga
Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers.
Cancer research 2011;71(5):1871-82.
2011: Todd W Miller; Brent N Rexer; Joan T Garrett; Carlos L Arteaga
Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer.
Breast cancer research : BCR 2011;13(6):224.
2011: Carlos L Arteaga
ERBB receptors in cancer: signaling from the inside.
Breast cancer research : BCR 2011;13(2):304.
2010: S E Wang; Y Yu; T L Criswell; L M Debusk; P C Lin; R Zent; D H Johnson; X Ren; Carlos L Arteaga
Oncogenic mutations regulate tumor microenvironment through induction of growth factors and angiogenic mediators.
Oncogene 2010;29(23):3335-48.
2010: Carlos L Arteaga
Clinical development of phosphatidylinositol-3 kinase pathway inhibitors.
Current topics in microbiology and immunology 2010;347():189-208.
2009: Todd W Miller; James T Forbes; Chirayu Shah; Shelby K Wyatt; H Charles Manning; Maria G Olivares; Violeta Sanchez; Teresa C Dugger; Nara de Matos Granja; Archana Narasanna; Rebecca Cook; J Phillip Kennedy; Craig W Lindsley; Carlos L Arteaga
Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(23):7266-76.
2009: Alexander R A Anderson; Mohamed Hassanein; Kevin M Branch; Jenny Lu; Nichole A Lobdell; Julie Maier; David Basanta; Brandy Weidow; Archana Narasanna; Carlos L Arteaga; Albert B Reynolds; Vito Quaranta; Lourdes Estrada; Alissa M Weaver
Microenvironmental independence associated with tumor progression.
Cancer research 2009;69(22):8797-806.
2009: Elizabeth A Maher; Judy Mietz; Carlos L Arteaga; Ronald A DePinho; Suresh Mohla
Brain metastasis: opportunities in basic and translational research.
Cancer research 2009;69(15):6015-20.
2009: Chirayu Shah; Todd W Miller; Shelby K Wyatt; Eliot T McKinley; Maria Graciela Olivares; Violeta Sanchez; Donald D Nolting; Jason R Buck; Ping Zhao; M Sib Ansari; Ronald M Baldwin; John C Gore; Rachel Schiff; Carlos L Arteaga; H Charles Manning
Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(14):4712-21.
2009: Brent N Rexer; Ritwik Ghosh; Carlos L Arteaga
Inhibition of PI3K and MEK: it is all about combinations and biomarkers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(14):4518-20.
2009: Dmitriy Kedrin; Jeffrey Bruce Wyckoff; Pamela J Boimel; Salvatore J Coniglio; Nancy E Hynes; Carlos L Arteaga; Jeffrey E Segall
ERBB1 and ERBB2 have distinct functions in tumor cell invasion and intravasation.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(11):3733-9.
2009: Todd W Miller; Marianela Pérez-Torres; Archana Narasanna; Marta Guix; Olle Stål; Gizeh Pérez-Tenorio; Ana M Gonzalez-Angulo; Bryan T. J. Hennessy; Gordon B Mills; J Phillip Kennedy; Craig W Lindsley; Carlos L Arteaga
Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer.
Cancer research 2009;69(10):4192-201.
2009: John Virostko; Jingping Xie; Dennis E Hallahan; Carlos L Arteaga; John C Gore; H Charles Manning
A molecular imaging paradigm to rapidly profile response to angiogenesis-directed therapy in small animals.
Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging 2009;11(3):204-12.
2009: Sarah A Scott; Paige E Selvy; Jason R Buck; Hyekyung P Cho; Tracy Criswell; Ashley L Thomas; Michelle D Armstrong; Carlos L Arteaga; Craig W Lindsley; H Alex Brown
Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
Nature chemical biology 2009;5(2):108-17.
2009: Shizhen Emily Wang; Bin Xiang; Roy Zent; Vito Quaranta; Ambra Pozzi; Carlos L Arteaga
Transforming growth factor beta induces clustering of HER2 and integrins by activating Src-focal adhesion kinase and receptor association to the cytoskeleton.
Cancer research 2009;69(2):475-82.
2009: Brent N Rexer; Jeffrey A Engelman; Carlos L Arteaga
Overcoming resistance to tyrosine kinase inhibitors: lessons learned from cancer cells treated with EGFR antagonists.
Cell cycle (Georgetown, Tex.) 2009;8(1):18-22.
2008: Liping Li; Hong Wang; Eddy Yang; Carlos L Arteaga; Fen Xia
Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells.
Cancer research 2008;68(22):9141-6.
2008: Todd W Miller; Incheol Shin; Norio Kagawa; Dean B Evans; Michael R Waterman; Carlos L Arteaga
Aromatase is phosphorylated in situ at serine-118.
The Journal of steroid biochemistry and molecular biology 2008;112(1-3):95-101.
2008: Carlos L Arteaga; Anne O'Neill; Stacy L Moulder; Michael Pins; Joseph A Sparano; George W Sledge; Nancy E Davidson
A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(19):6277-83.
2008: Tracy Criswell; Nancy Dumont; Joey V Barnett; Carlos L Arteaga
Knockdown of the transforming growth factor-beta type III receptor impairs motility and invasion of metastatic cancer cells.
Cancer research 2008;68(18):7304-12.
2008: Shizhen Emily Wang; Bin Xiang; Marta Guix; Maria Graciela Olivares; Joel Parker; Christine H Chung; Atanasio Pandiella; Carlos L Arteaga
Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab.
Molecular and cellular biology 2008;28(18):5605-20.
2008: Abbes Belkhiri; Altaf A Dar; Dunfa Peng; Mohammad H Razvi; Cammie Rinehart; Carlos L Arteaga; Wael El-Rifai
Expression of t-DARPP mediates trastuzumab resistance in breast cancer cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(14):4564-71.
2008: Marta Guix; Anthony C Faber; Shizhen Emily Wang; Maria Graciela Olivares; Youngchul Song; Sherman Qu; Cammie Rinehart; Brenda Seidel; Douglas Yee; Carlos L Arteaga; Jeffrey A Engelman
Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.
The Journal of clinical investigation 2008;118(7):2609-19.
2008: Vicki L Keedy; Carlos L Arteaga; David H Johnson
Does gefitinib shorten lung cancer survival? Chaos redux.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(15):2428-30.
2008: Melinda E Sanders; Eduardo C Dias; Baogang J Xu; James A Mobley; Dean Billheimer; Heinrich Roder; Julia Grigorieva; Mitchell Dowsett; Carlos L Arteaga; Richard M Caprioli
Differentiating proteomic biomarkers in breast cancer by laser capture microdissection and MALDI MS.
Journal of proteome research 2008;7(4):1500-7.
2008: Jose Baselga; Mace L Rothenberg; Josep Tabernero; Joan Seoane; Thomas Daly; Ann Cleverly; Brandi Berry; Susanne K Rhoades; Chad A Ray; Jeffrey Fill; Daphne L Farrington; Lisa Anne Wallace; Jonathan M Yingling; Michael Lahn; Carlos L Arteaga; Michael A Carducci
TGF-beta signalling-related markers in cancer patients with bone metastasis.
Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 2008;13(2):217-36.
2008: Marta Guix; Nara de Matos Granja; Ingrid Meszoely; Theresa B Adkins; Bobbye M Wieman; Kerek E Frierson; Violeta Sanchez; Melinda E Sanders; Ana M Grau; Ingrid A Mayer; Gary Pestano; Yu Shyr; Senthil K Muthuswamy; Benjamin F Calvo; Helen Krontiras; Ian Krop; Mark C Kelley; Carlos L Arteaga
Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(6):897-906.
2008: Ayana Sawai; Sarat Chandarlapaty; Heidi Greulich; Mithat Gonen; Qing Ye; Carlos L Arteaga; William R Sellers; Neal Rosen; David B Solit
Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.
Cancer research 2008;68(2):589-96.
2008: seungchan yang; Kyungho Park; James Turkson; Carlos L Arteaga
Ligand-independent phosphorylation of Y869 (Y845) links mutant EGFR signaling to stat-mediated gene expression.
Experimental cell research 2008;314(2):413-9.
2008: Marta Guix; Ingrid A Mayer; Ingrid M Meszoely; Carlos L Arteaga
Evaluation of biological agents targeted at early-stage disease.
Breast cancer research : BCR 2008;10 Suppl 4():S25.
2007: Tracy Criswell; Carlos L Arteaga
Modulation of NFkappaB activity and E-cadherin by the type III transforming growth factor beta receptor regulates cell growth and motility.
The Journal of biological chemistry 2007;282(44):32491-500.
2007: Christoph A Ritter; Marianela Perez-Torres; Cammie Rinehart; Marta Guix; Teresa Dugger; Jeffrey A Engelman; Carlos L Arteaga
Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(16):4909-19.
2007: Li Yang; Joseph M Amann; Takefumi Kikuchi; Rut Porta; Marta Guix; Adriana Gonzalez; Kyung-Ho Park; Dean Billheimer; Carlos L Arteaga; Hsin-Hsiung Tai; Raymond DuBois; David P Carbone; David H Johnson
Inhibition of epidermal growth factor receptor signaling elevates 15-hydroxyprostaglandin dehydrogenase in non-small-cell lung cancer.
Cancer research 2007;67(12):5587-93.
2007: Carlos L Arteaga
HER3 and mutant EGFR meet MET.
Nature medicine 2007;13(6):675-7.
2007: Swati Biswas; Marta Guix; Cammie Rinehart; Teresa C Dugger; Anna Chytil; Harold L Moses; Michael L Freeman; Carlos L Arteaga
Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression.
The Journal of clinical investigation 2007;117(5):1305-13.
2007: Alyssa R Bonine-Summers; Mary E Aakre; Kimberly A Brown; Carlos L Arteaga; Jennifer A Pietenpol; Harold L Moses; Nikki Cheng
Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells.
Cancer biology & therapy 2007;6(4):561-70.
2007: Shizhen Emily Wang; Archana Narasanna; Corbin W Whitell; Frederick Y Wu; David B Friedman; Carlos L Arteaga
Convergence of p53 and transforming growth factor beta (TGFbeta) signaling on activating expression of the tumor suppressor gene maspin in mammary epithelial cells.
The Journal of biological chemistry 2007;282(8):5661-9.
2007: Carlos L Arteaga
Will single-time tumor profiling and a "guilt by association" approach allow us to outsmart HER2-positive breast cancer?
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(4):1071-3.
2007: Peter Hinow; Shizhen Emily Wang; Carlos L Arteaga; Glenn F Webb
relocating job wise? A mathematical model separates quantitatively the cytostatic and cytotoxic effects of a HER2 tyrosine kinase inhibitor.
Theoretical biology & medical modelling 2007;4():14.
2007: David B Friedman; Shizhen Emily Wang; Corbin Whitwell; Richard M Caprioli; Carlos L Arteaga
Multivariable difference gel electrophoresis and mass spectrometry: a case study on transforming growth factor-beta and ERBB2 signaling.
Molecular & cellular proteomics : MCP 2007;6(1):150-69.
2006: Marianela Perez-Torres; Marta Guix; Adriana Gonzalez; Carlos L Arteaga
Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations.
The Journal of biological chemistry 2006;281(52):40183-92.
2006: Incheol Shin; Carlos L Arteaga
Expression of active Akt protects against tamoxifen-induced apoptosis in MCF-7 Cells.
IUBMB life 2006;58(11):664-9.
2006: Shizhen Emily Wang; Incheol Shin; Frederick Y Wu; David B Friedman; Carlos L Arteaga
HER2/Neu (ErbB2) signaling to Rac1-Pak1 is temporally and spatially modulated by transforming growth factor beta.
Cancer research 2006;66(19):9591-600.
2006: Shimian Qu; Cammie Rinehart; Hsiao-Huei Wu; Shizhen Emily Wang; Bruce Carter; Hongbo Xin; Michael I Kotlikoff; Carlos L Arteaga
Gene targeting of ErbB3 using a Cre-mediated unidirectional DNA inversion strategy.
Genesis (New York, N.Y. : 2000) 2006;44(10):477-86.
2006: Dale S Cornett; James A Mobley; Eduardo C Dias; Malin Andersson; Carlos L Arteaga; Melinda E Sanders; Richard M Caprioli
A novel histology-directed strategy for MALDI-MS tissue profiling that improves throughput and cellular specificity in human breast cancer.
Molecular & cellular proteomics : MCP 2006;5(10):1975-83.
2006: Carlos L Arteaga
Can trastuzumab be effective against tumors with low HER2/Neu (ErbB2) receptors?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(23):3722-5.
2006: Swati Biswas; Tracy Criswell; Shizhen Emily Wang; Carlos L Arteaga
Inhibition of transforming growth factor-beta signaling in human cancer: targeting a tumor suppressor network as a therapeutic strategy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(14 Pt 1):4142-6.
2006: seungchan yang; Shimian Qu; Marianela Perez-Tores; Ayana Sawai; Neal Rosen; David B Solit; Carlos L Arteaga
Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors.
Cancer research 2006;66(14):6990-7.
2006: Shizhen Emily Wang; Archana Narasanna; Marianela Perez-Torres; Bin Xiang; Frederick Y Wu; seungchan yang; Graham Carpenter; Adi F Gazdar; Senthil K Muthuswamy; Carlos L Arteaga
HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.
Cancer cell 2006;10(1):25-38.
2006: Rebecca Cook; Incheol Shin; Jae Youn Yi; E Easterly; Mary Helen Barcellos-Hoff; J M Yingling; Roy Zent; Carlos L Arteaga
Activated type I TGFbeta receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression.
Oncogene 2006;25(24):3408-23.
2006: Carlos L Arteaga
EGF receptor mutations in lung cancer: from humans to mice and maybe back to humans.
Cancer cell 2006;9(6):421-3.
2006: Frederick Y Wu; Shizhen Emily Wang; Melinda E Sanders; Incheol Shin; Federico Rojo; Jose Baselga; Carlos L Arteaga
Reduction of cytosolic p27(Kip1) inhibits cancer cell motility, survival, and tumorigenicity.
Cancer research 2006;66(4):2162-72.
2006: Incheol Shin; Todd Miller; Carlos L Arteaga
ErbB receptor signaling and therapeutic resistance to aromatase inhibitors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(3 Pt 2):1008s-1012s.
2006: Steven E Come; Aman U Buzdar; James N Ingle; Carlos L Arteaga; Myles Brown; Mitch Dowsett; Susan G Hilsenbeck; Rakesh Kumar; Stephen R D Johnston; Adrian V Lee; Soonmyung Paik; Kathleen I Pritchard; Eric P Winer; Carol Hart
Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: conference summary statement.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(3 Pt 2):997s-1000s.
2006: Carlos L Arteaga
Inhibition of TGFbeta signaling in cancer therapy.
Current opinion in genetics & development 2006;16(1):30-7.
2005: Nikki Cheng; Neil A Bhowmick; Anna Chytil; Agnieszka E Gorksa; Kimberly A Brown; Rebecca Cook; Carlos L Arteaga; Eric G Neilson; Simon W Hayward; Harold L Moses
Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks.
Oncogene 2005;24(32):5053-68.
2005: Shizhen Emily Wang; Frederick Y Wu; Incheol Shin; Shimian Qu; Carlos L Arteaga
Transforming growth factor {beta} (TGF-{beta})-Smad target gene protein tyrosine phosphatase receptor type kappa is required for TGF-{beta} function.
Molecular and cellular biology 2005;25(11):4703-15.
2005: José Baselga; Carlos L Arteaga
Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(11):2445-59.
2005: Incheol Shin; Jennifer Edl; Swati Biswas; P Charles Lin; Raymond L Mernaugh; Carlos L Arteaga
Proapoptotic activity of cell-permeable anti-Akt single-chain antibodies.
Cancer research 2005;65(7):2815-24.
2005: Jae Youn Yi; Incheol Shin; Carlos L Arteaga
Type I transforming growth factor beta receptor binds to and activates phosphatidylinositol 3-kinase.
The Journal of biological chemistry 2005;280(11):10870-6.
2005: Incheol Shin; Jeremy Rotty; Frederick Y Wu; Carlos L Arteaga
Phosphorylation of p27Kip1 at Thr-157 interferes with its association with importin alpha during G1 and prevents nuclear re-entry.
The Journal of biological chemistry 2005;280(7):6055-63.
2005: Andrei V Bakin; Nina V Stourman; SEKHAR KONJETI; Cammie Rinehart; Xuexian Yan; Michael J (Michael) Meredith; Carlos L Arteaga; Michael L Freeman
Smad3-ATF3 signaling mediates TGF-beta suppression of genes encoding Phase II detoxifying proteins.
Free radical biology & medicine 2005;38(3):375-87.
2005: Rebecca Cook; Nancy Dumont; Carlos L Arteaga
Dual role of transforming growth factor beta in mammary tumorigenesis and metastatic progression.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(2 Pt 2):937s-43s.
2005: Steven E Come; Aman U Buzdar; James N Ingle; Carlos L Arteaga; Angela Brodie; GRaham Colditz; Stephen R D Johnston; Vessela N Kristensen; Per Eystein Lønning; Donald P McDonnell; C Kent Osborne; Jose Russo; Richard J Santen; Douglas Yee; Carol S Hart
Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(2 Pt 2):861s-4s.
2004: Michelle L Reyzer; Robert L Caldwell; Teresa C Dugger; James T Forbes; Christoph A Ritter; Marta Guix; Carlos L Arteaga; Richard M Caprioli
Early changes in protein expression detected by mass spectrometry predict tumor response to molecular therapeutics.
Cancer research 2004;64(24):9093-100.
2004: Rebecca Cook; Hirokazu Kurokawa; Yasuhiro Koh; James T Forbes; L Renee Roebuck; Mary Helen Barcellos-Hoff; Susan E Moody; Lewis A Chodosh; Carlos L Arteaga
Conditional overexpression of active transforming growth factor beta1 in vivo accelerates metastases of transgenic mammary tumors.
Cancer research 2004;64(24):9002-11.
2004: Christoph A Ritter; Roberto Bianco; Teresa C Dugger; J Forbes; Shimian Qu; Cammie Rinehart; W King; Carlos L Arteaga
Mechanisms of resistance development against trastuzumab (Herceptin) in an in vivo breast cancer model.
International journal of clinical pharmacology and therapeutics 2004;42(11):642-3.
2004: Yukiko Ueda; Shizhen Wang; Nancy Dumont; Jae Youn Yi; Yasuhiro Koh; Carlos L Arteaga
Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks transforming growth factor beta-induced cell motility.
The Journal of biological chemistry 2004;279(23):24505-13.
2004: Carlos L Arteaga; Jose Baselga
Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them?
Cancer cell 2004;5(6):525-31.
2004: Carlos L Arteaga
Selecting the right patient for tumor therapy.
Nature medicine 2004;10(6):577-8.
2004: Carlos L Arteaga; CRISTINA TRUICA
Challenges in the development of anti-epidermal growth factor receptor therapies in breast cancer.
Seminars in oncology 2004;31(1 Suppl 3):3-8.
2004: Reade B Roberts; Carlos L Arteaga; David Threadgill
Modeling the cancer patient with genetically engineered mice: prediction of toxicity from molecule-targeted therapies.
Cancer cell 2004;5(2):115-20.
2004: Kimberly A Brown; Richard L Roberts; Carlos L Arteaga; Brian K Law
Transforming growth factor-beta induces Cdk2 relocalization to the cytoplasm coincident with dephosphorylation of retinoblastoma tumor suppressor protein.
Breast cancer research : BCR 2004;6(2):R130-9.
2004: Carlos L Arteaga
Cdk inhibitor p27Kip1 and hormone dependence in breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(1 Pt 2):368S-71S.
2004: Steven E Come; Aman U Buzdar; Carlos L Arteaga; Mina J Bissell; Myles Brown; Matthew J Ellis; Paul E Goss; Jeffrey E Green; James N Ingle; Adrian V Lee; Daniel Medina; Robert I Nicholson; Richard J Santen; Rachel Schiff; Carol S Hart
Proceedings of the Third International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(1 Pt 2):327S-330S.
2003: Carlos L Arteaga
EGF receptor as a therapeutic target: patient selection and mechanisms of resistance to receptor-targeted drugs.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(23 Suppl):289s-291s.
2003: C Kent Osborne; Carlos L Arteaga
Role of molecular and genetic markers in breast cancer treatment decisions.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(23 Suppl):285s-287s.
2003: Rebecca Cook; Yasuhiro Koh; L Renee Roebuck; Melinda E Sanders; Dana M Brantley-Sieders; Agnieszka E Gorska; Harold L Moses; Carlos L Arteaga
Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor beta1.
Molecular and cellular biology 2003;23(23):8691-703.
2003: Carlos L Arteaga
Inhibiting tyrosine kinases: successes and limitations.
Cancer biology & therapy 2003;2(4 Suppl 1):S79-83.
2003: David H Johnson; Carlos L Arteaga
Gefitinib in recurrent non-small-cell lung cancer: an IDEAL trial?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(12):2227-9.
2003: Stacy L Moulder; Carlos L Arteaga
A Phase I/II Trial of trastuzumab and gefitinib in patients with Metastatic Breast Cancer that overexpresses HER2/neu (ErbB-2).
Clinical breast cancer 2003;4(2):142-5.
2003: Nancy Dumont; Carlos L Arteaga
Targeting the TGF beta signaling network in human neoplasia.
Cancer cell 2003;3(6):531-6.
2003: Carlos L Arteaga
Targeting HER1/EGFR: a molecular approach to cancer therapy.
Seminars in oncology 2003;30(3 Suppl 7):3-14.
2003: Keith E Matheny; Christopher E Barbieri; Joe Sniezek; Carlos L Arteaga; Jennifer A Pietenpol
Inhibition of epidermal growth factor receptor signaling decreases p63 expression in head and neck squamous carcinoma cells.
The Laryngoscope 2003;113(6):936-9.
2003: Roberto Bianco; Incheol Shin; Christoph A Ritter; F Michael Yakes; Andrea Basso; Neal Rosen; Junji Tsurutani; Phillip A Dennis; Gordon B Mills; Carlos L Arteaga
Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors.
Oncogene 2003;22(18):2812-22.
2003: Carlos L Arteaga; Jose Baselga
Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(5):1579-89.
2003: James J Kobie; Rita S Wu; Robert A Kurt; Sunming Lou; Miranda K Adelman; Luke Whitesell; Lalitha V Ramanathapuram; Carlos L Arteaga; Emmanuel T Akporiaye
Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines.
Cancer research 2003;63(8):1860-4.
2003: Carlos L Arteaga
Molecular therapeutics: is one promiscuous drug against multiple targets better than combinations of molecule-specific drugs?
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(4):1231-2.
2003: Carlos L Arteaga
ErbB-targeted therapeutic approaches in human cancer.
Experimental cell research 2003;284(1):122-30.
2003: Christoph A Ritter; Carlos L Arteaga
The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors.
Seminars in oncology 2003;30(1 Suppl 1):3-11.
2003: Nancy Dumont; Carlos L Arteaga
A kinase-inactive type II TGFbeta receptor impairs BMP signaling in human breast cancer cells.
Biochemical and biophysical research communications 2003;301(1):108-12.
2003: Nancy Dumont; Andrei V Bakin; Carlos L Arteaga
Autocrine transforming growth factor-beta signaling mediates Smad-independent motility in human cancer cells.
The Journal of biological chemistry 2003;278(5):3275-85.
2003: Carlos L Arteaga
Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer.
Breast cancer research : BCR 2003;5(2):96-100.
2003: Hirokazu Kurokawa; Carlos L Arteaga
ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(1 Pt 2):511S-5S.
2003: Steven E Come; Aman U Buzdar; Carlos L Arteaga; Angela Brodie; Nancy E Davidson; Mitch Dowsett; James N Ingle; Stephen R D Johnston; Adrian V Lee; C Kent Osborne; Kathleen I Pritchard; Victor G Vogel; Eric P Winer; Carol S Hart
Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(1 Pt 2):443S-6S.
2002: Nancy Dumont; Carlos L Arteaga
The tumor microenvironment: a potential arbitrator of the tumor suppressive and promoting actions of TGFbeta.
Differentiation; research in biological diversity 2002;70(9-10):574-82.
2002: Kenneth B Ewan; Rhonda L Henshall-Powell; Shraddha A Ravani; Maria Jose Pajares; Carlos L Arteaga; Ray Warters; Rosemary J Akhurst; Mary Helen Barcellos-Hoff
Transforming growth factor-beta1 mediates cellular response to DNA damage in situ.
Cancer research 2002;62(20):5627-31.
2002: Carlos L Arteaga
Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia.
Seminars in oncology 2002;29(5 Suppl 14):3-9.
2002: Yasushi Adachi; Choon-Taek Lee; Keith Coffee; Noboru Yamagata; Joyce E Ohm; Kyung-Ho Park; Mikhail M Dikov; Sorena Nadaf; Carlos L Arteaga; David P Carbone
Effects of genetic blockade of the insulin-like growth factor receptor in human colon cancer cell lines.
Gastroenterology 2002;123(4):1191-204.
2002: Incheol Shin; F Michael Yakes; Federico Rojo; Nah-Young Shin; Andrei V Bakin; Jose Baselga; Carlos L Arteaga
PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization.
Nature medicine 2002;8(10):1145-52.
2002: Jae Youn Yi; Kyu Chung Hur; EunAh Lee; Yong Jae Jin; Carlos L Arteaga; Young Sook Son
TGFbeta1 -mediated epithelial to mesenchymal transition is accompanied by invasion in the SiHa cell line.
European journal of cell biology 2002;81(8):457-68.
2002: Andrei V Bakin; Cammie Rinehart; Anne K Tomlinson; Carlos L Arteaga
p38 mitogen-activated protein kinase is required for TGFbeta-mediated fibroblastic transdifferentiation and cell migration.
Journal of cell science 2002;115(Pt 15):3193-206.
2002: F Michael Yakes; Wichai Chinratanalab; Christoph A Ritter; Walter King; Steven A Seelig; Carlos L Arteaga
Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.
Cancer research 2002;62(14):4132-41.
2002: Carlos L Arteaga; Stacy L Moulder; F Michael Yakes
HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer.
Seminars in oncology 2002;29(3 Suppl 11):4-10.
2002: Rebecca Cook; Nancy Dumont; Christoph A Ritter; Teresa C Dugger; Dana M Brantley; Jin Chen; Evangeline Easterly; L Renee Roebuck; Sarah Ryan; Philip J Gotwals; Victor E Koteliansky; Carlos L Arteaga
Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases.
The Journal of clinical investigation 2002;109(12):1551-9.
2002: Rebecca Cook; Lenferink Anne; Brian Law; Elizabeth Hamilton; Dana M Brantley; L Renee Roebuck; Carlos L Arteaga
ErbB2/Neu-induced, cyclin D1-dependent transformation is accelerated in p27-haploinsufficient mammary epithelial cells but impaired in p27-null cells.
Molecular and cellular biology 2002;22(7):2204-19.
2002: Carlos L Arteaga; Fadlo R Khuri; Geoffrey Krystal; Said Sebti
Overview of rationale and clinical trials with signal transduction inhibitors in lung cancer.
Seminars in oncology 2002;29(1 Suppl 4):15-26.
2002: Carlos L Arteaga
Epidermal growth factor receptor dependence in human tumors: more than just expression?
The oncologist 2002;7 Suppl 4():31-9.
2001: Stacy L Moulder; F Michael Yakes; Senthil K Muthuswamy; Roberto Bianco; JF Simpson; Carlos L Arteaga
Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Cancer research 2001;61(24):8887-95.
2001: Hirokazu Kurokawa; Carlos L Arteaga
Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(12 Suppl):4436s-4442s; discussion 4411s-4412s.
2001: Carlos L Arteaga; Wichai Chinratanalab; M B Carter
Inhibitors of HER2/neu (erbB-2) signal transduction.
Seminars in oncology 2001;28(6 Suppl 18):30-5.
2001: Incheol Shin; Andrei V Bakin; Ulrich Rodeck; A Brunet; Carlos L Arteaga
Transforming growth factor beta enhances epithelial cell survival via Akt-dependent regulation of FKHRL1.
Molecular biology of the cell 2001;12(11):3328-39.
2001: Carlos L Arteaga; D H Johnson
Tyrosine kinase inhibitors-ZD1839 (Iressa).
Current opinion in oncology 2001;13(6):491-8.
2001: D Busse; F Michael Yakes; Lenferink Anne; Carlos L Arteaga
Tyrosine kinase inhibitors: rationale, mechanisms of action, and implications for drug resistance.
Seminars in oncology 2001;28(5 Suppl 16):47-55.
2001: Carlos L Arteaga
The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(18 Suppl):32S-40S.
2001: Lenferink Anne; D Busse; W M Flanagan; F Michael Yakes; Carlos L Arteaga
ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways.
Cancer research 2001;61(17):6583-91.
2001: Rebecca Cook; Lenferink Anne; J Simpson; Dana M Brantley; L Renee Roebuck; F Michael Yakes; Carlos L Arteaga
Cyclin-dependent kinase inhibitor p27(Kip1) is required for mouse mammary gland morphogenesis and function.
The Journal of cell biology 2001;153(5):917-32.
2001: Neil A Bhowmick; Mayshan Ghiassi; Andrei V Bakin; Mary E Aakre; Christopher A Lundquist; Michael Eugene Engel; Carlos L Arteaga; Harold L Moses
Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism.
Molecular biology of the cell 2001;12(1):27-36.
2001: JA McEarchern; James J Kobie; V Mack; Rita S Wu; Linda C Meade-Tollin; Carlos L Arteaga; N Dumont; David G Besselsen; E Seftor; Mary J C Hendrix; Emmanuel Katsanis; Emmanuel T Akporiaye
Invasion and metastasis of a mammary tumor involves TGF-beta signaling.
International journal of cancer. Journal international du cancer 2001;91(1):76-82.
2000: D Busse; R S Doughty; Carlos L Arteaga
HER-2/neu (erbB-2) and the cell cycle.
Seminars in oncology 2000;27(6 Suppl 11):3-8; discussion 92-100.
2000: Andrei V Bakin; A K Tomlinson; Neil A Bhowmick; Harold L Moses; Carlos L Arteaga
Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration.
The Journal of biological chemistry 2000;275(47):36803-10.
2000: Hirokazu Kurokawa; Lenferink Anne; JF Simpson; Paul I Pisacane; Mark X Sliwkowski; James T Forbes; Carlos L Arteaga
Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells.
Cancer research 2000;60(20):5887-94.
2000: Lenferink Anne; JF Simpson; LK Shawver; Robert J Coffey; James T Forbes; Carlos L Arteaga
Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(17):9609-14.
2000: D Busse; R S Doughty; TT Ramsey; William E Russell; James O Price; W M Flanagan; LK Shawver; Carlos L Arteaga
Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity.
The Journal of biological chemistry 2000;275(10):6987-95.
2000: Helenice Gobbi; Carlos L Arteaga; Roy A Jensen; Jean F Simpson; William D Dupont; Sandra J Olson; Peggy A Schuyler; W Dale Plummer; David L Page
Loss of expression of transforming growth factor beta type II receptor correlates with high tumour grade in human breast in-situ and invasive carcinomas.
Histopathology 2000;36(2):168-77.
2000: Nancy Dumont; Carlos L Arteaga
Transforming growth factor-beta and breast cancer: Tumor promoting effects of transforming growth factor-beta.
Breast cancer research : BCR 2000;2(2):125-32.
1999: Helenice Gobbi; William D Dupont; Jean F Simpson; W Dale Plummer; Peggy A Schuyler; Sandra J Olson; Carlos L Arteaga; David L Page
Transforming growth factor-beta and breast cancer risk in women with mammary epithelial hyperplasia.
Journal of the National Cancer Institute 1999;91(24):2096-101.
1999: Carlos L Arteaga
Foundations of molecular therapies in breast carcinoma.
Journal of mammary gland biology and neoplasia 1999;4(4):333-5.
1999: DK Srivastava; I Husain; Carlos L Arteaga; Samuel H Wilson
DNA polymerase beta expression differences in selected human tumors and cell lines.
Carcinogenesis 1999;20(6):1049-54.
1999: Carlos L Arteaga; KM Koli; Teresa C Dugger; Robert Clarke
Reversal of tamoxifen resistance of human breast carcinomas in vivo by neutralizing antibodies to transforming growth factor-beta.
Journal of the National Cancer Institute 1999;91(1):46-53.
1998: T Ohmori; J L Yang; James O Price; Carlos L Arteaga
Blockade of tumor cell transforming growth factor-betas enhances cell cycle progression and sensitizes human breast carcinoma cells to cytotoxic chemotherapy.
Experimental cell research 1998;245(2):350-9.
1998: T Ohmori; Carlos L Arteaga
Protein kinase C epsilon translocation and phosphorylation by cis-diamminedichloroplatinum(II) (CDDP): potential role in CDDP-mediated cytotoxicity.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1998;9(4):345-53.
1998: Fortunato Ciardiello; M Dixit; G di Isernia; Vincenzo Damiano; Roberto Bianco; Angelo Raffaele Bianco; Carlos L Arteaga; Giampaolo Tortora
Down-regulation of type I protein kinase A by transfection of human breast cancer cells with an epidermal growth factor receptor antisense expression vector.
Breast cancer research and treatment 1998;47(1):57-62.
1998: Y Ko; KM Koli; SS Banerji; Wenhui Li; Elizabeth Zborowska; James Willson; Michael G Brattain; Carlos L Arteaga
A kinase-defective transforming growth factor-beta receptor type II is a dominant-negative regulator for human breast carcinoma MCF-7 cells.
International journal of oncology 1998;12(1):87-94.
1997: Carlos L Arteaga; TT Ramsey; LK Shawver; Cheryl A Guyer
Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site.
The Journal of biological chemistry 1997;272(37):23247-54.
1997: KM Koli; TT Ramsey; Y Ko; Teresa C Dugger; Michael G Brattain; Carlos L Arteaga
Blockade of transforming growth factor-beta signaling does not abrogate antiestrogen-induced growth inhibition of human breast carcinoma cells.
The Journal of biological chemistry 1997;272(13):8296-302.
1997: KM Koli; Carlos L Arteaga
Processing of the transforming growth factor beta type I and II receptors. Biosynthesis and ligand-induced regulation.
The Journal of biological chemistry 1997;272(10):6423-7.
1997: Mrinalini Dixit; J L Yang; M C Poirier; James O Price; P A Andrews; Carlos L Arteaga
Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA.
Journal of the National Cancer Institute 1997;89(5):365-73.
1997: KM Koli; Carlos L Arteaga
Predominant cytosolic localization of type II transforming growth factor beta receptors in human breast carcinoma cells.
Cancer research 1997;57(5):970-7.
1996: KM Koli; Carlos L Arteaga
Complex role of tumor cell transforming growth factor (TGF)-beta s on breast carcinoma progression.
Journal of mammary gland biology and neoplasia 1996;1(4):373-80.
1996: Carlos L Arteaga; H L Moses
TGF-beta in mammary development and neoplasia.
Journal of mammary gland biology and neoplasia 1996;1(4):327-9.
1996: William J Muller; Carlos L Arteaga; Senthil Muthuswamy; Peter M Siegel; M A Webster; Robert Cardiff; Katherine S Meise; F Li; S A Halter; Robert J Coffey
Synergistic interaction of the Neu proto-oncogene product and transforming growth factor alpha in the mammary epithelium of transgenic mice.
Molecular and cellular biology 1996;16(10):5726-36.
1996: Carlos L Arteaga; Jeffrey T Holt
Tissue-targeted antisense c-fos retroviral vector inhibits established breast cancer xenografts in nude mice.
Cancer research 1996;56(5):1098-1103.
1996: Jeffrey T Holt; M E Thompson; C Szabo; C Robinson-Benion; Carlos L Arteaga; Mary-Claire King; Roy A Jensen
Growth retardation and tumour inhibition by BRCA1.
Nature genetics 1996;12(3):298-302.
1996: Pierosandro Tagliaferri; Giampaolo Tortora; Rosario Guarrasi; Vincenzo Damiano; A Ruggiero; D Morelli; Michele Caraglia; Roberto Bianco; G di Isernia; Stefano Pepe; Carlos L Arteaga; B C Langton-Webster; Angelo Raffaele Bianco; Fortunato Ciardiello
Differential sensitivity to non-major histocompatibility complex-restricted recombinant interleukin 2-activated lymphocyte killing of human mammary epithelial MCF-10A cells overexpressing oncogenes or protein kinase A subunits.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(1):207-14.
1996: Carlos L Arteaga; Teresa C Dugger; S D Hurd
The multifunctional role of transforming growth factor (TGF)-beta s on mammary epithelial cell biology.
Breast cancer research and treatment 1996;38(1):49-56.
1994: Carlos L Arteaga; S D Hurd; Teresa C Dugger; A R Winnier; J B Robertson
Epidermal growth factor receptors in human breast carcinoma cells: a potential selective target for transforming growth factor alpha-Pseudomonas exotoxin 40 fusion protein.
Cancer research 1994;54(17):4703-9.
1994: M H Disatnik; A R Winnier; Daria Mochly-Rosen; Carlos L Arteaga
Distinct responses of protein kinase C isozymes to c-erbB-2 activation in SKBR-3 human breast carcinoma cells.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1994;5(8):873-80.
1994: Carlos L Arteaga; A R Winnier; M C Poirier; D M Lopez-Larraza; Laura K Shawver; S D Hurd; S J Stewart
p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair.
Cancer research 1994;54(14):3758-65.
1994: Laura K Shawver; E Mann; S S Elliger; Teresa C Dugger; Carlos L Arteaga
Ligand-like effects induced by anti-c-erbB-2 antibodies do not correlate with and are not required for growth inhibition of human carcinoma cells.
Cancer research 1994;54(5):1367-73.
1994: M D Johnson; M Horiba; A R Winnier; Carlos L Arteaga
The epidermal growth factor receptor is associated with phospholipase C-gamma 1 in meningiomas.
Human pathology 1994;25(2):146-53.
1994: Harold L Moses; Carlos L Arteaga; M G Alexandrow; L Dagnino; M Kawabata; D F Pierce; R Serra
TGF beta regulation of cell proliferation.
Princess Takamatsu symposia 1994;24():250-63.
1993: Carlos L Arteaga; S D Hurd; A R Winnier; M D Johnson; B M Fendly; J T Forbes
Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression.
The Journal of clinical investigation 1993;92(6):2569-76.
1993: S M Hernández-Sotomayor; Carlos L Arteaga; C Soler; Graham Carpenter
Epidermal growth factor stimulates substrate-selective protein-tyrosine-phosphatase activity.
Proceedings of the National Academy of Sciences of the United States of America 1993;90(16):7691-5.
1993: S A Halter; A R Winnier; Carlos L Arteaga
Pretreatment with vitamin A inhibits transforming growth factor alpha stimulation of human mammary carcinoma cells.
Journal of cellular physiology 1993;156(1):80-7.
1993: Carlos L Arteaga; T Carty-Dugger; Harold L Moses; S D Hurd; Jennifer A Pietenpol
Transforming growth factor beta 1 can induce estrogen-independent tumorigenicity of human breast cancer cells in athymic mice.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1993;4(3):193-201.
1993: Carlos L Arteaga; Teresa C Dugger; A R Winnier; J T Forbes
Evidence for a positive role of transforming growth factor-beta in human breast cancer cell tumorigenesis.
Journal of cellular biochemistry. Supplement 1993;17G():187-93.
1992: M Romano; W H Polk; Joseph Awad; Carlos L Arteaga; Lillian B Nanney; Michael J Wargovich; E R Kraus; C R Boland; Robert J Coffey
Transforming growth factor alpha protection against drug-induced injury to the rat gastric mucosa in vivo.
The Journal of clinical investigation 1992;90(6):2409-21.
1992: Carlos L Arteaga; R J Coffey
Transforming growth factor-beta isoforms in mammary neoplasia: more questions than answers.
Human pathology 1992;23(1):1-3.
1992: Carlos L Arteaga
Interference of the IGF system as a strategy to inhibit breast cancer growth.
Breast cancer research and treatment 1992;22(1):101-6.
1991: Carlos L Arteaga; M D Johnson; G Todderud; Robert J Coffey; Graham Carpenter; David L Page
Elevated content of the tyrosine kinase substrate phospholipase C-gamma 1 in primary human breast carcinomas.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(23):10435-9.
1991: Carlos L Arteaga; C Kent Osborne
Growth factors as mediators of estrogen/antiestrogen action in human breast cancer cells.
Cancer treatment and research 1991;53():289-304.
1990: C Kent Osborne; David R Clemmons; Carlos L Arteaga
Regulation of breast cancer growth by insulin-like growth factors.
The Journal of steroid biochemistry and molecular biology 1990;37(6):805-9.
1990: Carlos L Arteaga; Robert J Coffey; Teresa C Dugger; C M McCutchen; Harold L Moses; R M Lyons
Growth stimulation of human breast cancer cells with anti-transforming growth factor beta antibodies: evidence for negative autocrine regulation by transforming growth factor beta.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1990;1(8):367-74.
1990: C Kent Osborne; Carlos L Arteaga
Autocrine and paracrine growth regulation of breast cancer: clinical implications.
Breast cancer research and treatment 1990;15(1):3-11.
1989: Carlos L Arteaga; C Kent Osborne
Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor.
Cancer research 1989;49(22):6237-41.
1989: Carlos L Arteaga; L J Kitten; E B Coronado; S Jacobs; F C Kull; D C Allred; C Kent Osborne
Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice.
The Journal of clinical investigation 1989;84(5):1418-23.
1989: Carlos L Arteaga; T D Brown; John Kuhn; H S Shen; T J O'Rourke; K Beougher; H J Brentzel; Daniel Von Hoff; G R Weiss
Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390).
Cancer research 1989;49(16):4648-53.
1989: Carlos L Arteaga; G M Clark
Inefficacy of methylglyoxal bis(guanylhydrazone) (MGBG) in patients with recurrent head and neck squamous cell carcinoma.
Investigational new drugs 1989;7(2-3):281-3.
1989: C Kent Osborne; L Kitten; Carlos L Arteaga
Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(6):710-7.
1988: Carlos L Arteaga; E Coronado; C Kent Osborne
Blockade of the epidermal growth factor receptor inhibits transforming growth factor alpha-induced but not estrogen-induced growth of hormone-dependent human breast cancer.
Molecular endocrinology (Baltimore, Md.) 1988;2(11):1064-9.
1988: Carlos L Arteaga; A R Hanauske; Gary M Clark; C Kent Osborne; P Hazarika; R L Pardue; F Tio; Daniel Von Hoff
Immunoreactive alpha transforming growth factor activity in effusions from cancer patients as a marker of tumor burden and patient prognosis.
Cancer research 1988;48(17):5023-8.
1988: Carlos L Arteaga; A K Tandon; Daniel Von Hoff; C Kent Osborne
Transforming growth factor beta: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells.
Cancer research 1988;48(14):3898-904.
1988: A R Hanauske; Carlos L Arteaga; Gary M Clark; J Buchok; M Marshall; P Hazarika; R L Pardue; Daniel Von Hoff
Determination of transforming growth factor activity in effusions from cancer patients.
Cancer 1988;61(9):1832-7.
1988: G R Weiss; Carlos L Arteaga; T D Brown; J B Craig; G S Harman; K A Havlin; J M Koeller; John Kuhn; Daniel Von Hoff
New anticancer agents.
Cancer chemotherapy and biological response modifiers 1988;10():85-116.
1987: Carlos L Arteaga; B J Forseth; Gary M Clark; Daniel Von Hoff
A radiometric method for evaluation of chemotherapy sensitivity: results of screening a panel of human breast cancer cell lines.
Cancer research 1987;47(23):6248-53.
1987: Carlos L Arteaga; D L Kisner; A Goodman; Daniel Von Hoff
Elliptinium, a DNA intercalating agent with broad antitumor activity in a human tumor cloning system.
European journal of cancer & clinical oncology 1987;23(11):1621-6.
1987: A R Hanauske; C Kent Osborne; Gary C Chamness; Gary M Clark; B J Forseth; J B Buchok; Carlos L Arteaga; Daniel Von Hoff
Alteration of EGF-receptor binding in human breast cancer cells by antineoplastic agents.
European journal of cancer & clinical oncology 1987;23(5):545-51.
1987: G R Weiss; Carlos L Arteaga; T D Brown; J B Craig; G S Harman; J M Koeller; John Kuhn; Daniel Von Hoff
New anticancer agents.
Cancer chemotherapy and biological response modifiers 1987;9():93-120.